Rhythm Pharmaceuticals (RYTM) Long-Term Investments (2021 - 2026)

Rhythm Pharmaceuticals (RYTM) has 6 years of Long-Term Investments data on file, last reported at $2.5 million in Q1 2026.

• Long-Term Investments for Q1 2026 came in at $2.5 million, down 64.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.5 million (down 64.75% YoY), and the FY2025 annual result was $3.3 million, down 55.15% from the prior year.
• Long-Term Investments slipped to $2.5 million in Q1 2026 per RYTM's latest filing, from $3.3 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $18.4 million in Q1 2022 and troughed at $2.2 million in Q2 2025.
• A 5-year average of $11.3 million and a median of $13.8 million in 2024 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2022 and 2025: Long-Term Investments jumped 48.26% in 2022, then slumped 82.59% in 2025.
• A 5-year view of Long-Term Investments shows it stood at $16.7 million in 2022, then retreated by 9.94% to $15.0 million in 2023, then plunged by 51.16% to $7.3 million in 2024, then sank by 55.15% to $3.3 million in 2025, then fell by 23.37% to $2.5 million in 2026.
• Business Quant data shows RYTM's Long-Term Investments at $2.5 million in Q1 2026, $3.3 million in Q4 2025, and $2.5 million in Q3 2025.